Minerva Neurosciences, Inc. has received a second notice from The Nasdaq Stock Market stating that the company's market value has been below the required minimum for continued listing for 31 consecutive business days. They were given until October 7, 2024, to regain compliance but failed to do so. The company now intends to request a hearing before a Nasdaq Hearings Panel to avoid delisting. There is no certainty that the extension will be granted or that Minerva will meet the listing requirements in the future.